Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.5 USD | +0.49% | -3.00% | -27.73% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.73% | 2.2B | |
-2.76% | 103B | |
+1.34% | 95.28B | |
+1.46% | 22.15B | |
-15.87% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.33% | 16.05B | |
+4.84% | 13.68B | |
+32.94% | 12.17B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating